These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 8674002)

  • 41. Fadrozole versus megestrol acetate: a double-blind randomised trial in advanced breast cancer.
    Bezwoda WR; Gudgeon A; Falkson G; Jordaan JP; Goedhals L
    Oncology; 1998; 55(5):416-20. PubMed ID: 9732218
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma.
    Costa LA; Kopreski MS; Demers LM; Chinchilli VM; Santen RJ; Harvey HA; Lipton A
    Cancer; 1999 Jan; 85(1):100-3. PubMed ID: 9921980
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The carcinoembryonic antigen as a potential prognostic marker for neuroendocrine carcinoma of the breast.
    Su CH; Chang H; Chen CJ; Liu LC; Wang HC; Lane HY; Bau DT
    Anticancer Res; 2012 Jan; 32(1):183-8. PubMed ID: 22213305
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein.
    Yamauchi H; O'Neill A; Gelman R; Carney W; Tenney DY; Hösch S; Hayes DF
    J Clin Oncol; 1997 Jul; 15(7):2518-25. PubMed ID: 9215820
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HER-2/neu serum levels vis-à-vis hormonal response in metastatic breast cancer.
    Panasci LC
    J Clin Oncol; 2002 Aug; 20(15):3357; author reply 3357. PubMed ID: 12149314
    [No Abstract]   [Full Text] [Related]  

  • 46. Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer.
    Cook GB; Neaman IE; Goldblatt JL; Cambetas DR; Hussain M; Lüftner D; Yeung KK; Chan DW; Schwartz MK; Allard WJ
    Anticancer Res; 2001; 21(2B):1465-70. PubMed ID: 11396233
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ADVIA Centaur HER-2/neu shows value in monitoring patients with metastatic breast cancer.
    Lüftner D; Cheli C; Mickelson K; Sampson E; Possinger K
    Int J Biol Markers; 2004; 19(3):175-82. PubMed ID: 15503818
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Elevated plasma endoglin (CD105) predicts decreased response and survival in a metastatic breast cancer trial of hormone therapy.
    Vo MN; Evans M; Leitzel K; Ali SM; Wilson M; Demers L; Evans DB; Lipton A
    Breast Cancer Res Treat; 2010 Feb; 119(3):767-71. PubMed ID: 19115106
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients.
    Leitzel K; Teramoto Y; Sampson E; Mauceri J; Langton BC; Demers L; Podczaski E; Harvey H; Shambaugh S; Volas G
    J Clin Oncol; 1992 Sep; 10(9):1436-43. PubMed ID: 1355522
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serum HER2 and CA 15-3 in breast cancer patients.
    Baskić D; Ristić P; Pavlović S; Arsenijević N
    J BUON; 2004; 9(3):289-94. PubMed ID: 17415828
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical utility of serial serum c-erbB-2 determinations in the follow-up of breast cancer patients.
    Fehm T; Gebauer G; Jäger W
    Breast Cancer Res Treat; 2002 Sep; 75(2):97-106. PubMed ID: 12243512
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The potential use of saliva to detect recurrence of disease in women with breast carcinoma.
    Bigler LR; Streckfus CF; Copeland L; Burns R; Dai X; Kuhn M; Martin P; Bigler SA
    J Oral Pathol Med; 2002 Aug; 31(7):421-31. PubMed ID: 12165061
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A pilot study of stanozolol for advanced breast carcinoma.
    Daniel F; Rao DG; Tyrrell CJ
    Cancer; 1991 Jun; 67(12):2966-8. PubMed ID: 2044043
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The neu-oncogene product in serum and tissue of patients with breast carcinoma.
    Kath R; Höffken K; Otte C; Metz K; Scheulen ME; Hülskamp F; Seeber S
    Ann Oncol; 1993 Aug; 4(7):585-90. PubMed ID: 8103351
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serum c-erB-2 levels in monitoring of operable breast cancer patients.
    Imoto S; Kitoh T; Hasebe T
    Jpn J Clin Oncol; 1999 Jul; 29(7):336-9. PubMed ID: 10470658
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic significance of serum c-erbB-2 protein in breast cancer patients.
    Willsher PC; Beaver J; Pinder S; Bell JA; Ellis IO; Blamey RW; Robertson JF
    Breast Cancer Res Treat; 1996; 40(3):251-5. PubMed ID: 8883967
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Elevated serum c-erbB-2 protein levels in patients with pancreatic cancer: correlation to metastasis and shorter survival.
    Okada N; Ohshio G; Yamaki K; Imamura T; Imamura M
    Oncology; 1995; 52(5):392-6. PubMed ID: 7637957
    [TBL] [Abstract][Full Text] [Related]  

  • 58. c-erbB-2 in serum of patients with breast cancer.
    Harris L; Luftner D; Jäger W; Robertson JF
    Int J Biol Markers; 1999; 14(1):8-15. PubMed ID: 10367244
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Detection of c-erbB-2 related protein in sera from breast cancer patients. Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumour.
    Andersen TI; Paus E; Nesland JM; McKenzie SJ; Børresen AL
    Acta Oncol; 1995; 34(4):499-504. PubMed ID: 7605658
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Clinical study of serum ErbB-2 protein using sandwich radioimmunometric assay (ErbB-2 IRMA 'Eiken')].
    Sugano K; Kawai T; Ishii M; Koyama H; Kitajima M; Kasumi F; Demura R; Nakayama T; Okabe H; Mori S
    Gan To Kagaku Ryoho; 1994 Jul; 21(8):1245-53. PubMed ID: 7913312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.